Skip to main content
OpenTrials
Completed

NCT Number: NCT01093443

Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days

In this prospective study, the investigators would like to show whether ovarian stimulation with pretreatment of a GnRH antagonist during 3 consecutive days at initiation of the cycle, is possible.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–39 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

UZ Brussel

Jette, Brussels Capital, 1090, Belgium

About this study

A recently accepted study demonstrated that raised progesterone levels can be normalized through administration of a GnRH antagonist during three subsequent days prior to the start of gonadotropin stimulation in a GnRH antagonist protocol. This regimen, after normalisation of the progesterone value, allows controlled ovarian hyperstimulation (COH). Since this regimen is valid in case of elevated progesterone, GnRH antagonists pretreatment may prove to be a valid tool for scheduling IVF treatment in patients with normal progesterone values on day 2 of the cycle. In this prospective randomised trial, the investigators study the impact of administration of a GnRH antagonist during 3 consecutive days at initiation of the cycle.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • < 39 years old on day of randomisation
  • FSH < 12 (in the early follicular phase)
  • Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation.
  • Regular menstrual cycles of 21-35 days, presumed to be ovulatory.
  • BMI between 18 and 29 (both inclusive)
  • 1st or 2nd trial
  • IVF or ICSI
  • Randomisation at out-patient clinic

Exclusion criteria

  • ≥ 39 years old on day of randomisation
  • Endometriosis ≥ grade 3
  • PCOS

Treatment and study plan

ovarian stimulation

Drug

rFSH with GnRH antagonists

Primary outcomes

  1. Endocrine profile

    Time frame: up to 9 months

    The purpose is to assess the endocrine profile in each treatment group

Secondary outcomes

  1. Pregnancy rate

    Time frame: up to 9 months

    The purpose is to study the pregnancy rate in each treatment group

Sponsors and collaborators

Lead sponsor

Universitair Ziekenhuis Brussel

Other

Registry information

Official study title

Administration of a GnRH Antagonist During 3 Days at Initiation of the Cycle: Impact on the Stimulation in IVF/ICSI

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Mar 25, 2010
Registry last updated
Oct 11, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.